| As |
ZIO-101 (As2) |
Metalloproteomics by GE-ICP-MS |
Binds to and disrupts dimerisation of H3.3 |
248
|
| Ru |
NAMI-A (Ru4) |
Proteomics by MALDI-TOF or LC-ESI/MS–MS |
NAMI-A and RAPTA-T similar mechanism; NIT2, TMK, HINT1 and PFD3 up-regulated, POLE3 down-regulated |
250
|
| Ru |
Plecstatin-1 (Ru15†) |
Proteomics by LC-MS/MS |
Targets plectin |
251
|
| Ru |
RAPTA-C (Ru12) |
Proteomics by shotgun and pull-down |
Influences cytokines midkine, pleiotrophin, fibroblast growth factor-binding protein 3, FAM32A |
252
|
| Os |
FY26 (Os4) |
RNA transcriptomics and proteomics by reverse-phase protein arrays |
Shifts cellular metabolism to oxidative phosphorylation, up-regulates ATM, p53 and p21 |
220
|
| Pt |
Cisplatin (Pt1) |
Genomics by damage-seq, XR-seq, RNA-seq |
Per1 upregulated. Transcription-coupled repair and global repair high in liver |
253
|
| Proteomics by nanoLC-MS/MS |
HMGB1 binds to cisplatin cross-linked ODN specifically |
254
|
| Metabolomics by GC-MS, LC-MS |
27 potential biomarkers defined related to cisplatin-induced nephrotoxicity |
255
|
| Au |
[Au(TPP)]Cl (Au4†) |
Proteomics by MALDI-TOF-MS |
Targets Hsp60 |
256
|
| Affinity-based proteome profiling SILAC |
246
|
